

## News Release

Lonza Group Ltd  
Muenchensteinerstrasse 38  
CH-4002 Basel, Switzerland  
[www.lonza.com](http://www.lonza.com)

### Lonza Successfully Starts Up Second Phase of Nansha API Facility

Basel, Switzerland, 6 August 2009 – Lonza continues the expansion of its activities in China. The successful start-up of the second phase of its large-scale API facility in Nansha is another milestone in the continued build-out of Lonza's cGMP chemical manufacturing capabilities.

Lonza's new API facility in Nansha, China combines state-of-the art facilities, industry-leading development services and advanced cGMP chemical manufacturing plants with Lonza's commitment to quality. The Nansha site is fully integrated with facilities for administration, research and development, a kilo lab, and both small-scale and large-scale production. Seventy scientists provide R&D Services in a 1000m<sup>2</sup> lab area.

"The build-out of our Nansha operations proceeds as planned and we are happy that the second phase went on-line in accordance with our timelines and budget," comments Uwe H. Böhlke, COO LCM, Exclusive Synthesis. "We are now able to offer our clients even greater flexibility as the newly added capacity operates with multiple train sizes."

The new large-scale production facility in Nansha is a five-train, multipurpose API manufacturing complex. With the completion of phase 2 the first three trains are fully operational, totalling 126m<sup>3</sup> of reactor volume. Off gases and waste water are treated in accordance with Lonza's global safety, health and environmental standards. The design of the facility allows for quick change over and is supported by reliable logistics in a key geographic location.

#### About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

**For further Information**

Lonza Group Ltd  
Head Corporate Communications  
Michael Frizberg  
Tel +41 61 316 8624  
Fax +41 61 316 9624  
michael.frizberg@lonza.com

Lonza Group Ltd  
Media Relations  
Dominik Werner  
Tel +41 61 316 8798  
Fax +41 61 316 9798  
dominik.werner@lonza.com

Lonza Group Ltd  
Investor Relations  
Alexandre Pasini  
Tel +41 61 316 8835  
Fax +41 61 316 9835  
alexandre.pasini@lonza.com